Zenas BioPharma, Inc. - 8-K Filing

Zenas BioPharma announced new data from its Phase 3 trial showing obexelimab's sustained clinical activity and reduced glucocorticoid toxicity in IgG4-related disease. (Items: 7.01 Regulation FD Disclosure On October 12, 2026, the Company issued a press release announcing new data from its Phase 3 trial of obexelimab in, 9.01 Financial Statements and Exhibits)

SEC EDGAR · October 13, 2026, 10:03 UTC

Tickers: $ZBIO

Read the full article at SEC EDGAR

Part of the story Zenas BioPharma, Inc. - 8-K Filing (3 articles)

More Regulatory news

First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC